LILRB2 (BMS-986406 Biosimilar) Recombinant Monoclonal Antibody

This recombinant monoclonal antibody is developed as a research-grade biosimilar to BMS-986406, targeting LILRB2 (Leukocyte Immunoglobulin-Like Receptor B2), also known as ILT4 or CD85d. LILRB2 is an inhibitory immune checkpoint receptor expressed primarily on myeloid cells, including monocytes, macrophages, and dendritic cells. Upon ligand binding, LILRB2 delivers immunosuppressive signals that dampen immune responses and promote immune tolerance. This receptor plays a critical role in tumor immune evasion by suppressing antigen presentation and T cell activation within the tumor microenvironment. LILRB2 is implicated in various cancers, including acute myeloid leukemia, and contributes to resistance against immunotherapy by maintaining an immunosuppressive myeloid cell phenotype.

BMS-986406 is a clinical-stage therapeutic antibody designed to block LILRB2 function and restore anti-tumor immunity. This biosimilar antibody serves as a valuable research tool for investigating LILRB2-mediated immune regulation, studying myeloid cell function in cancer and inflammatory conditions, and exploring combination immunotherapy strategies. It enables researchers to examine checkpoint blockade mechanisms and evaluate potential therapeutic interventions targeting myeloid immunosuppression.